TherapeuticsMD (NASDAQ:TXMD) Trading Up 1.5% – What’s Next?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s stock price traded up 1.5% during mid-day trading on Thursday . The company traded as high as $2.07 and last traded at $2.00. 11,780 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 26,659 shares. The stock had previously closed at $1.97.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

TherapeuticsMD Price Performance

The company’s 50 day moving average is $2.07 and its two-hundred day moving average is $2.05. The firm has a market cap of $23.15 million, a P/E ratio of 33.33 and a beta of 0.60.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, May 12th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($6.12) by $6.13. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $19.77 million.

Hedge Funds Weigh In On TherapeuticsMD

A number of hedge funds and other institutional investors have recently made changes to their positions in TXMD. Citadel Advisors LLC lifted its holdings in shares of TherapeuticsMD by 125.5% during the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after acquiring an additional 19,073 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of TherapeuticsMD by 171.8% during the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after acquiring an additional 61,000 shares during the period. Finally, Tejara Capital Ltd lifted its holdings in shares of TherapeuticsMD by 1.9% during the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock worth $572,000 after acquiring an additional 6,649 shares during the period. 30.74% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.